Clinical trials are structured studies that examine the performance of investigational drugs in human patients.

This section of the Calando Pharmaceuticals website provides an update on the status of our clinical trials.

CALAA-01 Clinical Trials

Phase I Clinical Trial - Currently Recruiting

This is an open-label, dose-escalating study of the safety of intravenous CALAA-01 in Adults with solid tumors refractory to standard-of-care therapies. Patients who satisfy the inclusion and exclusion criteria will receive two, 21-day cycles of CALAA-01. A cycle will consist of four infusions administered on days 1, 3, 8, and 10 followed by 11 days of rest. If safe, a second 21-day cycle will be administered consisting of infusions on days 22, 24, 29 and 31 followed by 11 days of rest.

For additional information please visit Clinicaltrials.gov

IT-101 Clinical Trials

Phase I Clinical Trial - Currently Recruiting

This is an open-label, dose-escalation study of IT-101 administered in patients with solid tumor malignancies. Patients who satisfy the inclusion/exclusion criteria will receive injections of IT-101 every other week. Patients will be monitored for a response using RECIST criteria every 2 months.

For additional information please visit Clinicaltrials.gov

Phase II Clinical Trial – Currently Recruiting

For additional information please visit Clinicaltrials.gov